Press release
Leading Growth Driver in the Primary Biliary Cholangitis Market in 2025: Rising Smoking Rates Fueling Growth in the Primary Biliary Cholangitis Market Driver's Influence
Primary Biliary Cholangitis Market
The primary biliary cholangitis market has grown rapidly in recent years. It will grow from $0.98 billion in 2024 to $1.09 billion in 2025, at a CAGR of 11.8%. This growth is linked to rising disease awareness, increased global healthcare spending, strategic collaborations in healthcare, advocacy for patients, and government initiatives for liver health.
The primary biliary cholangitis market is expected to reach $1.6 billion by 2029, growing at a CAGR of 9.9%. Growth is driven by advancements in biomarker research, rare disease management efforts, clinical trial collaborations, patient-centric healthcare approaches, and a rising demand for liver transplants. Key trends include biomarker advancements, non-invasive diagnostic techniques, immunomodulatory therapies, AI integration, patient-reported outcomes in clinical trials, and emerging fibrosis-targeting therapies.
What Is Contributing to the Growth of the Primary Biliary Cholangitis Market?
The rise in smoking is likely to boost the primary biliary cholangitis (PBC) market. Smoking involves inhaling and exhaling tobacco smoke, which is a known risk factor for liver diseases, including PBC. Higher smoking rates can contribute to an increase in individuals requiring medical intervention for liver-related conditions. For instance, Statistics Canada reported in July 2023 that cigarette production in Canada increased by 2.2% compared to June 2023. Additionally, cigarette sales in June rose by 2.6%, reaching 1.4 billion units compared to May. Thus, the increasing prevalence of smoking is anticipated to accelerate the growth of the primary biliary cholangitis market.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp
Which Key Market Leaders Are Driving Primary Biliary Cholangitis Industry Growth?
Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc., TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.
What Are the Emerging Trends in the Primary Biliary Cholangitis Industry?
Companies in the primary biliary cholangitis market are concentrating on developing specialized treatments, including orphan drugs combining obeticholic acid (OCA) and bezafibrates, to secure market exclusivity. This combination aims to offer a more effective treatment for primary biliary cholangitis (PBC), enhancing patient outcomes. For instance, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, received orphan drug designation from the FDA for the combination of obeticholic acid (OCA) and bezafibrate, a PPAR agonist. Obeticholic acid (marketed as Ocaliva) is already approved for PBC in the US, and the new combination therapy seeks to provide improved treatment options for this progressive liver disease.
What Are the Main Segments in the Primary Biliary Cholangitis Market?
The primary biliary cholangitis market covered in this report is segmented -
1) By Treatment Type: Drugs, Liver Transplantation
2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses
3) By End-Users: Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies
2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant
Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report
Which Geographic Area Leads the Primary Biliary Cholangitis Market?
North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Is Covered In The Primary Biliary Cholangitis Global Market Report?
- Market Size Analysis: Analyze the Primary Biliary Cholangitis Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Primary Biliary Cholangitis Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Primary Biliary Cholangitis Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Primary Biliary Cholangitis Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13520
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leading Growth Driver in the Primary Biliary Cholangitis Market in 2025: Rising Smoking Rates Fueling Growth in the Primary Biliary Cholangitis Market Driver's Influence here
News-ID: 3853992 • Views: …
More Releases from The Business Research Company
Foam Tape Industry to Achieve $14.62 Billion Growth by 2029
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.
How Will the Foam Tape Market Grow by 2025 in Terms of Size and Growth?
In recent times, there has been significant growth in the market size for foam tape. It is projected to escalate from $10.02 billion in 2024 to $10.77 billion in 2025, demonstrating a compound annual growth rate (CAGR)…
Continuous Positive Airway Pressure (CPAP) Mask Market Expansion Outlook: $3.85 …
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.
What Is the Projected CAGR for the Continuous Positive Airway Pressure (CPAP) Mask Market from 2024 to 2025?
In recent times, the market size of the continuous positive airway pressure (cpap) mask has seen robust growth. The market is projected to rise from $2.83 billion in 2024 to $3 billion in 2025,…
Alkyd Coating Market to Record 7.5% CAGR Growth Through 2029 | Global Analysis R …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Alkyd Coating Market Outlook: How is the Market Expected to Grow by 2025?
The market size of alkyd coatings has experienced significant growth in the past few years. The market is projected to expand from $25.13 billion in 2024 to $26.74 billion in 2025, exhibiting a compound annual growth rate…
Water Free Skincare Market Analysis: $22.5 Billion by 2029 With a CAGR of 7%
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
Water Free Skincare Market Value Projection: How Much Will the Market Size by 2025?
The market size of waterless skincare has experienced a robust increase in recent years. The expected growth is from $15.96 billion in 2024 to $17.15 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%.…
More Releases for Primary
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
